GlassScriptPhysician profile
George L Austin
NPI 1952392276
$1,245.23
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $94.68 · 2021: $64.71 · 2022: $154 · 2023: $324 · 2024: $34.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $365.97 | 2019-2024 | Recarbrio, Dificid, Zerbaxa |
| W. L. Gore & Associates, INC. | $187.78 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $185.69 | 2019-2023 | Caldolor |
| Portola Pharmaceuticals, LLC | $123.33 | 2019-2020 | |
| Sanara Medtech INC. | $87.09 | 2023 | Celleraterx |
| Smith+Nephew, INC. | $62.46 | 2020-2023 | Collagenase Santyl, Grafix Pl |
| Allergan, INC. | $51.87 | 2019 | |
| Lifenet Health | $50.10 | 2023-2024 | Theragenesis Wound Matrix |
| Bioventus LLC | $48.51 | 2022-2023 | Theragenesis Bilayer Wound Matrix |
| Seagen INC. | $27.42 | 2020 | |
| Abbvie INC. | $22.47 | 2019 | |
| Melinta Therapeutics, LLC | $19.66 | 2023 | Kimyrsa, Rezzayo |
| Misonix INC | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.